DURHAM – Bioventus, the Durham-based life science company focusing on a variety of treatments targeting bones and joint pain, is another step closer to going public.
The company has priced its 8 million share offering at $13 each and looks to raise just over $100 million.
Shares are expected to begin trading after the offering closes Feb. 16 on the Nasdaq Global Market under the symbol “BVS.”
It’s the second time the company has prepared to go public. In 2016, Bioventus filed IPO papers only to withdraw them less than two months later.
Bioventus separates its business into three segments:
- The osteoarthritis joint pain treatment and joint preservation division consists of injectable treatments for osteoarthritis knee pain.
- The bone graft substitutes unit includes human tissue products designed to improve bone fusion rates after spinal fusion and other orthopedic procedures.
- The third division, minimally invasive fracture treatment, consists of medical devices that use ultrasound technology to promote bone growth.